Histone lysine demethylases (KDMs) are emerging as therapeutic targets in cancer. Development of potent KDM inhibitors may provide additional options for epigenomicsoriented therapies. Using a Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) functional demethylation assay, in combination with a high-content immunofluorescence imaging phenotypic screen, Matrix-Assisted Laser Desorption/Ionization-Fourier Transform Ion Cyclotron Resonance mass spectrometry (MALDI-FTICR MS) and Amplified Luminescent Proximity Homogeneous Assay (ALPHA), we identified geldanamycin, an inhibitor of heat shock protein 90 (Hsp90), as a novel inhibitor of JmjC-domain containing demethylases such as KDM4B. We further found that geldanamycin can destabilize the PAX3-FOXO1 fusion oncoprotein, an Hsp90 client, which is a driver of clinically unfavorable alveolar rhabdomyosarcoma (aRMS). We then hypothesized that dual inhibition of PAX3-FOXO1 and epigenetic modifiers of aRMS would have synergistic antitumor activity. We repurposed the geldanamycin analog 17-DMAG to target aRMS and found that 17-DMAG significantly delays tumor growth , extends survival in xenograft mouse models, and inhibits expression of PAX3-FOXO1 targets and multiple oncogenic pathways including MYC, E2F and NOTCH. In addition, the combination of 17-DMAG with conventional chemotherapy or the bromodomain inhibitor JQ1 significantly enhances therapeutic efficacy. In summary, we have identified geldanamycin and 17-DMAG as dual KDM/Hsp90 inhibitors and 17-DMAG is efficacious against PAX3-FOXO1-driven rhabdomyosarcoma.
Introduction
The heat shock pathway plays a significant role in promoting protein folding. It is activated in many tumors and provides transformed cells with a survival advantage by maintaining protein homeostasis. The heat shock protein 90 (Hsp90) is harnessed by cancer cells to facilitate the function of oncoproteins as a molecular chaperone 1, 2 ; hence, one important feature of cancer cells is their "addiction" to Hsp90 3 , making this a potential therapeutic vulnerability. Since the identification of the first prototype of Hsp90 inhibitor 4 , geldanamycin, numerous Hsp90 inhibitors have been developed and at least seventeen entered clinical trials 5 , including the geldanamycin analogs 17-AAG (17-N-allylamino-17demethoxygeldanamycin) and 17-DMAG (17-dimethylaminoethylamino-17demethoxygeldanamycin). However, Hsp90 inhibitors have not demonstrated significant clinical efficacy 6 . The inhibitory potency and affinity of geldanamycin and its analogs for the isolated Hsp90 protein was in the low micromolar range [7] [8] [9] , which is in contrast to their low nanomolar cellular antiproliferative activity [8] [9] [10] [11] , suggesting that the antiproliferative activity may be due to a mechanism other than via Hsp90 inhibition alone. A better understanding of the mechanisms of action of these Hsp90 inhibitors that underlie treatment response is key to improving their therapeutic activity and clinical outcomes.
Aberrant histone lysine methylation is commonly seen in a variety of cancers 12 , due to genetic alteration or dysregulated expression of histone lysine methyltransferases and histone lysine demethylases (KDMs) [13] [14] [15] [16] [17] [18] . The KDM4 (KDM4A-D) subfamily are Jumonjidomain containing KDMs, which are responsible for removing methyl groups from triand dimethylated H3K9 and H3K36 19 . KDM4B is particularly important and is involved in a variety of pathophysiological functions 20 . We and others have shown that KDM4B is a direct target of estrogen receptor alpha (ERα) and hypoxia-inducible factor 1 (HIF1) in ERα + breast cancer [21] [22] [23] [24] , and that it epigenetically regulates G2/M phase cell cycle gene expression 24 . In addition, KDM4B is a key molecule in androgen receptor (AR) signaling 25 , which epigenetically enhances AR transcriptional activity. Recently, we further showed that KDM4B is involved in neuroblastoma growth and tumor maintenance 26 . KDM4 members are also required for the transformation of pediatric leukemia driven by the fusion oncoprotein MLL-AF9 27, 28 . A recent study has shown that KDM4B is involved in the regulation of unfolded protein response (UPR) in PTEN-deficient triple-negative breast cancers, and genetic depletion or small molecule inhibition of KDM4B activates the UPR pathway, resulting in preferential apoptosis 29 . These data suggest that targeting KDM4B may enhance the efficacy of proteotoxic drugs such as Hsp90 inhibitors by further impairing oncoprotein folding.
Rhabdomyosarcoma (RMS) is a devastating myogenic cancer in children, adolescents and young adults 30, 31 . This soft tissue sarcoma is mainly classified into two histological subtypes, alveolar RMS (aRMS) and embryonal RMS (eRMS). aRMS is more aggressive, with a higher rate of metastasis and a poorer prognosis 30, 32, 33 . aRMS is primarily driven by the pathognomonic fusion oncoprotein PAX3-FOXO1 34, 35 or its variant PAX7-FOXO1.
Although current treatment modalities have steadily improved survival of RMS patients, the outcome for aRMS patients with metastatic disease remain dismal, underscoring the pressing need to develop novel therapies for this subset of patients.
We recently identified ciclopirox as a new KDM4B inhibitor 36 , which shows antitumor activity in neuroblastoma models. Here we further found that ciclopirox induces differentiation of aRMS cells and inhibits tumor growth in PAX3-FOXO1-positive aRMS xenografts, indicating that pharmacologically targeting KDM may have therapeutic benefit to aRMS, which promoted us to develop more potent KDM4B inhibitors. By using multiple orthogonal validation approaches, we identified the Hsp90 inhibitors, geldanamycin and its analog 17-DMAG 4,37 , as novel and potent KDM4 inhibitors. We also found that PAX3-FOXO1 is an Hsp90 client, which was destabilized by geldanamycin.
We therefore hypothesized that repurposing these ansamycins may achieve better efficacy against PAX3-FOXO1-driven aRMS. Indeed, 17-DMAG significantly delayed tumor growth. RNA-seq analysis showed that 17-DMAG affected multiple oncogenic pathways.
Immunohistochemical staining showed that angiogenesis was significantly reduced while cell death markers (Caspase 3 and TUNEL) were significantly increased by 17-DMAG.
The combination of 17-DMAG with conventional chemotherapy or the bromodomain inhibitor JQ1 further enhanced the antitumor efficacy in mouse xenograft models. These data indicate that dually targeting KDM and Hsp90 in aRMS by 17-DMAG provides a new paradigm for repurposing this old drug in targeted cancer therapy.
Results

TR-FRET demethylation assay identifies geldanamycin as a potent KDM4 inhibitor
We developed a primary 384-well format screening, Time-Resolved Fluorescence
Resonance Energy Transfer (TR-FRET) demethylation functional assay, to identify novel KDM4B inhibitors (Fig. 1A) . The assay uses a Terbium (Tb)-labeled anti-H3K9me2 antibody as a fluorescence donor, and an AF488 tagged streptavidin as a fluorescence acceptor that detects the biotinylated histone H3K9me2 peptide. When uninhibited, KDM4B converts the substrate H3K9me3 peptide to the product H3K9me2 peptide, which is recognized and bound by both the donor Tb-labelled antibody and acceptor AF488labelled streptavidin. The resulting proximity of the Tb donor and the AF488 acceptor elicits a fluorescence emission at 520 nm when excited at 340 nm. When the KDM4B activity is inhibited, less biotin-H3K9me2 is generated and the 520 nm emission signal (and the 520 nm/490 nm ratio) is reduced. We optimized the conditions by (1) (Supplementary Fig. 1A-1H ). Our TR-FRET assay displayed predictability and reproducibility of responses to known KDM4 inhibitors and showed a clear threshold between positive and negative responses ( Fig. 1B, 1C) . The high-throughput screening (HTS) statistical parameter Z'(Zprime) had an average value of 0.73 (0.55-0.87) from our pilot screen ( Fig. 1D) , indicating that the assay is robust and reproducible. On the basis of the optimized parameters, we performed a pilot screening of 3262 FDA-approved drugs and bioactive molecules and identified the Hsp90 inhibitor geldanamycin as a novel and potent KDM4B inhibitor with an IC50 of 50.1 nM ( Fig. 1E, 1F) .
We also designed a homogeneous time-resolved fluorescence resonance energy transfer assay (HTRF) that is similar to TR-FRET, but the fluorophore AF488 is replaced with AF647, which switches the light detection wavelength from 520 nm to 665 nm to avoid interference by intrinsically fluorescent compounds and reduce false positives. The HTRF assay obtained a comparable IC50 value (84.4 nM) for geldanamycin ( Fig. 1G) . The inhibition of KDM4B by geldanamycin appears to be KDM4B-mediated because omitting KDM4B abrogated the drug response relationship (Fig. 1H) . To test whether other nonansamycin Hsp90 inhibitors were able to inhibit KDM4B activity, we included additional Hsp90 inhibitors (Ganetespib, KW2478, SNX-5422, AT13387, NVP-AUY922, STA-4783 and XL888); none of them showed an activity >15% of inhibition to KDM4B ( Supplementary Fig.2 ). These data suggest geldanamycin, but not other non-ansamycin
Hsp90 inhibitors, inhibits KDM4B.
Orthogonal identification of geldanamycin as a KDM4 inhibitor by high-content
immunofluorescence imaging screen and a MALDI-FTICR mass spectrometry-based approach
We also developed an orthogonal phenotypic assay in parallel with the TR-FRET assay as a secondary screen. We made a retroviral vector to transfer the wild type KDM4B gene and a catalytically dead mutant of KDM4B (H189A), in which histidine 189 was replaced by alanine, resulting in the loss of iron binding activity, leading to the loss of demethylation function. We then transduced U2OS cells with these retroviral vectors ( Fig. 2A) . In our experience, many cell lines cannot tolerate overexpression of KDM4B, due, perhaps, to a DNA damage response to global loss of H3K9me3, but U2OS cells appeared to tolerate the overexpression and exhibited the expected global reduction of H3K9me3 by the wildtype KDM4B ( Fig. 2A) . We then used these cell lines to screen 2684 compounds and monitored the H3K9me3 levels with immunofluorescence imaging in 384-well plates. The Z-prime score reached 0.5 (data not shown), indicating that this assay is acceptable for screening. We again found that geldanamycin inhibited KDM4B, with an IC50 of 21.2 nM in the cell-based assay (Fig. 2B, 2C ). We further assessed the effect of geldanamycin and its analog 17-DMAG on KDM4B activity in U2OS cells via Western blot analysis ( Fig.   2D ). Both compounds blocked KDM4B catalytic activity on its H3K9me3 and H3K36me3 substrates in cells but not on H3K4me3, which is not a substrate of KDM4B ( Fig. 2D) . We performed a similar experiment in 293T cells expressing KDM4B or the catalytically dead mutant and included ciclopirox as a control. Geldanamycin, 17-DMAG, and ciclopirox greatly inhibited KDM4B activity in the cells expressing KDM4B, compared to those expressing the control or catalytically dead mutant ( Supplementary Fig. S3 ). These data indicate that both geldanamycin and its analog 17-DMAG inhibit KDM4B activity in cells.
To further validate the on-target of geldanamycin, we developed a Matrix-Assisted Laser Desorption/Ionization-Fourier Transform Ion Cyclotron Resonance (MALDI-FTICR) mass spectrometry-based approach, which is detailed in the Methods section. Again, we found that geldanamycin inhibited KDM4B activity with an IC50 of 1.24µM ( Fig. 2E, 2F ).
Although this method was less sensitive than our TR-FRET and immunofluorescence assays, it validated that KDM4B activity was inhibited by geldanamycin in vitro.
To determine the binding affinity of geldanamycin and the catalytic domain of KDM4B, we performed a Microscale Thermophoresis (MST) assay, which showed a Kd value of 540 nM ( Fig. 2G) . These data indicate a direct binding of geldanamycin and the catalytic domain of KDM4B.
Profiling of geldanamycin activity against KDM using ALPHA screen
To determine the selectivity of geldanamycin and its analogs 17-DMAG and 17-AAG against KDMs, an ALPHA screen was used to assess the KDM inhibitory activity of these ansamycins at 5 µM. Geldanamycin showed greatest inhibition to KDM4 and KDM5 subfamilies ( Fig. 3A) , which have highest sequence homology in comparison to other KDMs with a phylogenetic tree showing that KDM4 and KDM5 members are the closest neighbors ( Fig. 3A) . These data suggest the inhibitory activity of geldanamycin is correlated with JmjC domain structures. Interestingly, 17-DMAG had a broader inhibitory activity to KDMs including KDM3-6 ( Fig. 3A) . In contrast, 17-AAG showed a high inhibition to KDM4A and KDM4C (Fig. 3A) . We further determined the IC50 of the three ansamycin analogs to KDMs, and we chose 1-2 KDMs that were representatives of each subfamily. Geldanamycin has an IC50 below 1µM to KDM4B, KDM4C and KDM5A ( Fig.   3B ), while 17-DMAG had an IC50 below 1µM to KDM3A, KDM4B, KDM4C, KDM5A
and KDM6B ( Fig. 3B) . However, 17-AAG had an IC50 below 1µM to KDM4C and KDM5A ( Fig. 3B) . All three compounds were much less effective at inhibiting KDM1A (IC50>10µM), a flavin adenine dinucleotide-dependent amine oxidase domain containing KDM, which is structurally distinct from JmjC KDMs. All three compounds showed a reasonable dose-response relationship (Fig. 3C, 3D) . These data indicate that the inhibitory activity of ansamycins to KDMs depends on the JmjC domain and is impacted by the modifications at 17-position of the benzoquinone ring of the compounds (Fig. 3E) .
Geldanamycin promotes PAX3-FOXO1 degradation in aRMS cells
As an oncogenic transcription factor, PAX3-FOXO1 is difficult to target directly. Previous studies have shown a chaperone dependency of fusion oncoproteins such as BCR-ABL 38 , EML4-ALK 39 and EWS-FLI1 40 , as they are Hsp90 clients and are destabilized by Hsp90
inhibitors. Since chimeric oncoproteins do not exist in normal cells, we hypothesized that fusion proteins such as PAX3-FOXO1 may be more prone to degradation in the absence of cellular chaperone protein function. We examined whether PAX3-FOXO1 expression was downregulated by geldanamycin and 17-DMAG, known Hsp90 inhibitors.
Immunoprecipitation confirmed that PAX3-FOXO1 and Hsp90 physically complexed ( Fig. 4B) . Indeed, PAX3-FOXO1 expression was reduced by geldanamycin and 17-DMAG ( Fig. 4A) . Inhibition of Hsp90 often leads to proteasomal degradation of its clients 6 . Consistent with this, the downregulation of PAX3-FOXO1 by geldanamycin or 17-DMAG was rescued by MG132 ( Fig. 4C) , a reversible proteasome inhibitor. These data demonstrate that the PAX3-FOXO1 protein needs Hsp90 for its stabilization, providing the rational to target PAX3-FOXO1 protein stability by inhibiting Hsp90 activity. Thus, geldanamycin not only inhibits the enzymatic activity of KDM but also downregulates key oncoprotein levels by targeting Hsp90, thus making it a unique dual inhibitor.
17-DMAG suppresses tumor growth, inhibits tumor angiogenesis, and disrupts multiple oncogenic pathways
We previously identified ciclopirox as a KDM4 inhibitor that has antitumor activity in neuroblastoma models 36 . We have further shown that ciclopirox induced RMS cell differentiation and inhibited tumor growth in a PAX3-FOXO1-positive aRMS xenograft model ( Supplementary Fig. 4 ). We have also determined that KDM4 inhibition is a vulnerability of PAX3-FOXO1-driven RMS using a selective KDM4 inhibitor QC6352 41 (manuscript in preparation), which epigenetically impacts expression of PAX3-FOXO1 targets. We therefore hypothesized that geldanamycin/17-DMAG might be effective for PAX3-FOXO1-positive aRMS based on: (1) their ability to inhibit KDM4 activity; and (2) their ability to target PAX3-FOXO1 for proteasomal degradation. As geldanamycin has unfavorable pharmacokinetics in vivo and is associated with liver toxicity, we chose 17- extended mouse survival ( Fig. 5B) . In contrast, 17-AAG had only a very modest effect on tumor growth and survival ( Fig. 5A, 5B ). RNA-seq analysis of the treated xenografts showed that PAX3-FOXO1 targets such as FGFR4, were significantly downregulated by 17-DMAG but not 17-AAG ( Fig. 5C ). FGFR4 is known to be important for RMS tumor growth 42 . Gene set enrichment analysis (GSEA) showed that 17-DMAG significantly inhibited MYC, E2F and NOTCH pathways ( Fig. 5D) , all of which are essential to cancer cell growth, proliferation and survival. Immunohistochemical staining for the apoptosis marker Caspase 3 and a cell death marker TUNEL showed that 17-DMAG induced significant cancer cell death ( Fig. 5E ). In addition, the areas of blood vessels indicated by angiogenesis marker CD31, which labeled endothelial cells, were greatly reduced ( Fig.   5F ), indicating that 17-DMAG inhibits tumor angiogenesis. Taken together, 17-DMAG has potent antitumor effect and targets multiple oncogenic pathways in aRMS.
Combination of 17-DMAG with conventional chemotherapy or bromodomain inhibitor JQ1 enhances therapeutic efficacy
A recent preclinical study showed that combination of the Hsp90 inhibitor Ganetespib with Vincristine (VCR) and Irinotecan (IRN) significantly enhanced the tumor response in RMS xenograft models 43 . Considering that Ganetespib alone showed no significant effect on inhibition of RMS xenograft 43 while 17-DMAG significantly delayed tumor growth ( Fig.   5A ), we anticipated that the combination of 17-DMAG and VCR+IRN may obtain better efficacy. Indeed, combining 17-DMAG significantly improved the efficacy of VCR/IRN in two PAX3-FOXO1-positive RMS xenograft models implanted in NSG mice ( Fig. 6A-6F ). In the Rh30 xenograft model, all mice had complete response (CR) to the combination therapy while nearly all control mice had progressive disease (PD) when treated with 17-DMAG alone or chemotherapy alone ( Fig. 6A-6C ). In the Rh41 xenograft model, combination therapy also showed better response (11% stable disease, 22% partial response and 67% complete response ) than monotherapy ( Fig. 6D-6F ).
Finally, based on a recent study that showed PAX3-FOXO1 was dependent on BRD4 and that the bromodomain inhibitor JQ1 suppressed tumor growth 44 , we hypothesized that the combination of 17-DMAG and JQ1 would synergistically enhance the therapeutic efficacy.
In a PAX3-FOXO1-positive Rh41 xenograft model, the single agent modestly delayed tumor growth, while the combination significantly reduced tumor growth ( Supplementary   Fig. 6A-6C ). Taken together, 17-DMAG showed potent anti-tumor activity when combined with conventional therapy or targeted therapy.
Discussion
Geldanamycin, and its analog 17-AAG and 17-DMAG, are prototype Hsp90 inhibitors which bind N-terminal pocket of Hsp90 45 and have potent anticancer activity. However, the mechanism of action of these ansamycins is not entirely clear. It has been reported that geldanamycin and its analogs have inhibitory activity and binding affinity to Hsp90 in the range of 0.3-10 μM [7] [8] [9] , which is in contrast to the low nanomolar antiproliferative activity of the compounds in multiple cell lines in culture [8] [9] [10] [11] . Three major mechanisms were proposed to interpret the discrepancy of the 100-fold greater potency in cell culture. The first theory is ansamycins bind to and inhibit an Hsp90 multiprotein complex with much higher affinity than to Hsp90 alone 46 . The second explanation is that the physicochemical properties of the ansamycins result in its intracellular accumulation from cell culture media 9 , leading to highly potent antiproliferative activity. The third possible reason may be due to geldanamycin's time-dependent, tight binding to Hsp90 47 . However, in this study, we identified geldanamycin and 17-DMAG as potent KDM inhibitors using multiple orthogonal validation approaches (TR-FRET, high-content immunofluorescence, MALDI-FTICR mass spectrometry, alpha screen and MST assay), convincingly demonstrating that these compounds are epigenetic modulators. Other chemotypes of Hsp90 inhibitors showed no direct KDM inhibition, indicating that geldanamycin has unique features being a dual inhibitor of KDM/Hsp90.
KDMs play an important role in carcinogenesis, metastasis and therapy resistance 48 .
Pharmacologically targeting KDM effectively inhibits tumor growth in multiple preclinical models. A selective KDM1 inhibitor has entered clinical trial in Ewing sarcoma treatment.
We recently identified an antifungal drug ciclopirox as a JmjC-domain containing KDM inhibitor, which targets KDM4B and suppresses neuroblastoma growth 36 . Here, we further Geldanamycin is a natural antibiotic isolated as the fermentation product of Streptomyces hygroscopicus, a bacterial strain widely distributed in nature, especially in the soil. Activity profiling of geldanamycin against KDMs showed that geldanamycin is more selective to inhibit human KDM4 and KDM5 members, two closest subfamilies in the KDM phylogenetic tree (Fig. 3A) . Why would a bacterium produce an antibiotic that is able to dually inhibit KDM and Hsp90? One naïve speculation is that it may help bacteria more effectively defend surrounding competitors such as other bacterial strains or fungi.
Although bacteria do not have homologs of KDM4 and KDM5, they do have JmjC domain containing proteins and Hsp90 homologs. However, fungi have homologs of KDM4 and KDM5 based on the phylogenetic analysis ( Supplementary Fig. 5 ). 17 54 . These data indicate that geldanamycin has an evolutionary selectivity to JmjC KDMs. While the structural basis for selectivity of geldanamycin and its analogs against KDM remains to be solved, the selectivity is probably determined by the differences of 17-position of benzoquinone ring (17-methoxy group of geldanamycin, 17-dimethylaminoethylamino of 17-DMAG, and 17-N-allylamino of 17-AAG). Based on structural studies, this position is highly solvent exposed in the Hsp90-Geldanamycin crystal complex and is a poor candidate for additional Hsp90 contacts 45 , suggesting that it is not essential to Hsp90 binding.
In summary, we identified Hsp90 inhibitors, geldanamycin and its analog 17-DMAG, as novel and potent KDM inhibitors. We also found that PAX3-FOXO1 is a Hsp90 client, which was destabilized by geldanamycin. Our findings support a concept that PAX3-FOXO1 creates an epigenetic dependency to KDMs and chaperone dependency to Hsp90, and thus dually targeting KDMs and Hsp90 is a potentially valuable therapeutic option for PAX3-FOXO1-driven aRMS (Supplementary Fig. 7) . However, more side-effects might be also expected. Nevertheless, in addition to inhibiting Hsp90 and KDMs, the therapeutic efficacy of 17-DMAG could also be due to other off-targeting molecules.
Materials and Methods
Cell lines and reagents
Cell lines 293T, U2OS, Rh30, Rh41 cell lines were purchased from ATCC and validated 
MALDI-FTICR mass spectrometry-based demethylation assay
To assess the inhibition potency of geldanamycin and its analogs, we used a MALDI-TOF Where IP and IS are the ion intensities of product and substrate, respectively. Values for % Turnover were then normalized based on negative and positive controls. 
MS
ALPHA Screen demethylation assay
Phylogenetic tree analysis
Amino acid sequences of KDM domains of histone lysine demethylases were aligned with Clustal Omega program (https://www.ebi.ac.uk/Tools/msa/clustalo/) and the phylogenetic tree was generated using neighbor-joining method, which was shown using iTOL program (https://itol.embl.de).
RNA-seq
Total RNA was extracted from xenograft tissues by RNeasy Mini Kit (cat. # 74104) from QIAGEN. Paired-end sequencing was performed using the High-Seq platform with 100bp read length. Reads were aligned to the human GRCh37-lite using SJCRH's Strongarm pipeline. Counts per gene were obtained using htseq-count version 0.6.1 with Gencode vM5 level 1and 2 gene annotations. Counts were normalized with VOOM and analyzed with LIMMA within the R statistical environment. Significance was defined as having a false discovery rate (FDR) <0.05. VOOM normalized counts were analyzed with Gene Set Enrichment Analysis (GSEA) 55 .
Western blot
Cells were washed twice with ice-cold phosphate-buffered saline (PBS) and then directly (1:5,000), anti-total H3 (1:2,000), anti-H3K4me3 (1:2,000), anti-H3K9me3 (1:2,000) and anti-H3K36me3 (1:2,000). Next day, membranes were washed 3 times (each wash for 5 minutes) with PBS-T at room temperature. Protected from light, membranes were then incubated with goat anti-mouse or goat anti-rabbit HRP-conjugated secondary antibodies (1:5,000) for 1 hour at room temperature. Then, membranes were washed 3 times (each wash for 5 minutes) with PBS-T at room temperature. Lastly, membranes were incubated for 1 minute at room temperature with SuperSignal West Pico PLUS Chemiluminescent Substrate (34580, Thermo Fisher Scientific), and the bound antigen-antibody complexes were visualized using Odyssey Fc Imaging System (LI-COR Corp., Lincoln, NE). 
Immunoprecipitation
Animal experiments
All murine experiments were done in accordance with a protocol approved by the Vincristine was administered in a dose of 0.38 mg/kg via IP injection once daily every
week. Vincristine was dissolved in 100% saline. Irinotecan was administered in a dose of 1.25 mg/kg via IP injection once daily, for 5 days on and 2 days off schedule. Irinotecan was dissolved in 5% DMSO and 95% saline. Mice were sacrificed because of an adverse event before they had completed 14d and were removed from the data set. Tumor response:
For individual mice, progressive disease (PD) was defined as < 50% regression from initial volume during the study period and > 25% increase in initial volume at the end of study period. Stable disease (SD) was defined as < 50% regression from initial volume during the study period and ≤ 25% increase in initial volume at the end of the study. Partial response (PR) was defined as a tumor volume regression ≥50% for at least one time point but with measurable tumor ( 0.10 cm 3 ). Complete response (CR) was defined as a disappearance of measurable tumor mass (< 0.10 cm 3 ) for at least one time point.
Statistical analysis
To determine statistical significance, the unpaired, two-tailed Student t test was calculated using the t test calculator available on GraphPad Prism 8.0 software. A p value of less than 0.05 was considered statistically significant. Kaplan-Meier survival analysis was calculated using log-rank (Mantel-Cox) method in GraphPad Prism 8.0 software.
The Kruskal Wallis test was utilized to determine if there was a statistically significant different among the 4 treatment groups at each time point. The exact Wilcoxon Rank Sum test was utilized to determine if there was a statistically significant difference between receiving one treatment vs receiving the combination treatment. All statistical analyses ≥ were conducted in SAS 9.4 and a two-sided significance level of p<0.05 was determined a priori. 
